 
 
Savient Pharmaceuticals, Inc.
One Tower Center, 14th Floor
East Brunswick, New Jersey 08816
  
 
KRYSTEXXA ® (pegloticase) 
Protocol No. M0401 
Observational Study of the Use of KRYSTEXXA ® 
(pegloticase) in Adult Hyperuricemic Patients with Gout 
Refractory to Conventional Therapy 
Authors:  
Document type: Clinical study protocol 
Development phase: Phase 4 
Document status: FINAL  
Original protocol rele ase date: 11-July-2011 
Amendment 1 release date Not applicable 
Number of pages: 51 
Property of Savient Pharmaceuticals, Inc. 
Confidential 
May not be divulged, publishe d or otherwise disclosed 
to any other parties without the pr ior written permission of Savient 

Savient Pharmaceuticals, Inc. Confidential Page 2 
Protocol M0401 FINAL  11 July 2011 KRYSTEXXA ® (pegloticase) 
 
Savient signature page  
Compound:  pegloticase  
IND #:   BB-IND 10122  
Protocol number: M0401 
Study Title : Observational study of the use of KRYSTEXXA ® (pegloticase) in adult 
hyperuricemic patients with gout refractory to conventional therapy  
Sponsor:   Savient Pharmaceuticals, Inc.  
   One Tower Center, 14th Floor 
   East Brunswick, NJ 08816 
    
Sponsor Representative: 
 
 
 
Vice President, Clinical Affairs 
and Interim Chief Medical Officer signature   date 
 

Savient Pharmaceuticals, Inc. Confidential Page 3 
Protocol M0401 FINAL  11 July 2011 KRYSTEXXA ® (pegloticase) 
 
Investigator signature page 
 
Protocol number: M0401 
 
Study Title:  Observational study of the use of KRYSTEXXA ® (pegloticase) in adult 
hyperuricemic patients with gout re fractory to conventional therapy 
 
Investigator: 
I agree to conduct this clinical study in accordance with the design and specific provisions of this 
protocol. I agree to report all information or data in accordance with the protocol and, in 
particular, I agree to report a ll serious adverse expe riences as defined in Section 3.8 of this 
protocol. I also agree to collect and handle all cl inical specimens according to this protocol and 
supporting manuals. 
  
__________________________ 
Principal/primary Investigator 
(type or print name) signature   date 
    
Savient Pharmaceuticals, Inc. Confidential Page 4 
Protocol M0401 FINAL  11 July 2011 KRYSTEXXA ® (pegloticase) 
 
LIST OF EXTERNAL FACILITIES 
Sponsor’s representative for study conduct 
 
 
929 North Front Street, Wilmington, NC 28401-3331 
 
Bioanalytical laboratory facility 
 
Millipore Corporation 15 Research Park Drive, Saint Charles, MO 63304 
 
Central laboratory facility 
 LabConnect LLC 100 LabConnect Lane, Johnson City, TN 37615 
 

Savient Pharmaceuticals, Inc. Confidential Page 5 
Protocol M0401 FINAL  11 July 2011 KRYSTEXXA ® (pegloticase) 
 
TABLE OF CONTENTS  
SAVIENT SIGNATURE PAGE.....................................................................................................2  
INVESTIGATOR SI GNATURE PAGE........................................................................................3  
LIST OF EXTERNA L FACILITIES.............................................................................................4  
TABLE OF CO NTENTS................................................................................................................5  
LIST OF TABLES................................................................................................................. ..........8  
LIST OF FIGURES................................................................................................................ .........8  
LIST OF ABBREVIATIONS.........................................................................................................9  
PROTOCOL SYNOPSIS.............................................................................................................. 10 
CONTACT INFORMATION.......................................................................................................15  
1 INTRODUCTION.............................................................................................................16  
1.1 Disease Background............................................................................................................1 6 
1.2 KRYSTEXXA Background ................................................................................................16  
1.2.1 Efficacy Assessments in Clinical Studies of KRYSTEXXA .................................17  
1.2.2 Safety Assessments in Clinical Studies of KRYSTEXXA ....................................17  
1.3 Study Rationale ................................................................................................................ ...19 
2 STUDY OBJECTIVES.....................................................................................................19  
2.1 Primary........................................................................................................................ ........19  
2.2 Secondary...................................................................................................................... ......19  
3 INVESTIGATIONAL PLAN...........................................................................................19  
3.1 Overall Study Design ..........................................................................................................1 9 
3.2 Discussion of Design........................................................................................................... 20 
3.3 Study Population ............................................................................................................... ..21 
3.3.1 Patient Population ..................................................................................................21  
3.3.2 Inclusion and Exclusion Criteria ............................................................................22  
3.3.2.1  Inclusion Criteria .........................................................................................22  
3.3.2.2  Exclusion Criteria ........................................................................................22  
3.4 Treatments..................................................................................................................... ......22  
3.4.1 Investigational Drug and Reference Therapy.........................................................22  
3.4.1.1  Investigational Drug.....................................................................................22  
Savient Pharmaceuticals, Inc. Confidential Page 6 
Protocol M0401 FINAL  11 July 2011 KRYSTEXXA ® (pegloticase) 
 
3.4.1.2  Reference therapy ........................................................................................23  
3.4.2 Treatment Assignment ...........................................................................................23  
3.4.3 Blinding..................................................................................................................23  
3.4.4 Treatment Compliance ...........................................................................................23  
3.4.5 Concomitant Therapy.............................................................................................23  
3.5 Visit Schedules and Assessments........................................................................................23  
3.5.1 Screening Procedures .............................................................................................24  
3.5.2 Study Procedures....................................................................................................25  
3.5.2.1  Visits 1 through 26.......................................................................................25  
3.5.2.2  Visits 13 and 26 ...........................................................................................26  
3.5.2.3  Visit 27: End of Study..................................................................................26  
3.5.3 Early Treatment  Discontinuation Procedures........................................................26  
3.5.4 Early Discontinuation from the Study....................................................................27  
3.5.5 Interruption of Treatment .......................................................................................28  
3.5.6 Patient Discontinuation from Study .......................................................................28  
3.5.7 Gout flare Prophylax is and Treatment ...................................................................28  
3.5.7.1  Gout flare Prophylaxis .................................................................................28  
3.5.7.2  Gout flare Treatment....................................................................................29  
3.5.8 Infusion Reactions..................................................................................................29  
3.5.8.1  Infusion Reaction Prophylaxis.....................................................................29  
3.5.8.2  Anaphylaxis .................................................................................................29  
3.5.8.3  Management of Infusion-related Adverse Events........................................30  
3.6 Efficacy Asse ssments..........................................................................................................3 1 
3.6.1 Serum Uric Acid Levels.........................................................................................31  
3.6.2 Clinical Outcomes ..................................................................................................31  
3.6.2.1  Number of Swollen Joints and Tender Joints ..............................................31  
3.6.2.2  Gout flares....................................................................................................31  
3.6.2.3  Number of Tophi..........................................................................................31  
3.7 Safety A ssessments ............................................................................................................. 31 
3.7.1 Adverse Event Profile ............................................................................................31  
3.7.2 Laboratory Evaluations ..........................................................................................32  
3.7.3 Vital Signs..............................................................................................................32  
3.7.4 Physical Examination.............................................................................................32  
3.7.5 Antibody Formation ...............................................................................................32  
Savient Pharmaceuticals, Inc. Confidential Page 7 
Protocol M0401 FINAL  11 July 2011 KRYSTEXXA ® (pegloticase) 
 
3.8 Adverse Events................................................................................................................. ...33 
3.8.1 Adverse Event Definitions .....................................................................................33  
3.8.1.1  Adverse Event..............................................................................................33  
3.8.1.2  Serious Adverse Event.................................................................................33  
3.8.1.3  Adverse Event Classifications .....................................................................34  
3.8.2 Adverse Event Evaluation Criteria.........................................................................34  
3.8.2.1  Relationship .................................................................................................34  
3.8.3 Adverse Event Reporting .......................................................................................35  
3.9 Adjudication Committees....................................................................................................35  
3.10 Steering Committee............................................................................................................. 36 
4 PROTOCOL AMENDMENTS, OTHER CH ANGES IN STUDY CONDUCT.........36  
4.1 Protocol Amendments.........................................................................................................36  
4.2 Other Changes in Study Conduct........................................................................................36  
5 DATA MANAGEMENT..................................................................................................36  
5.1 Data Collection....................................................................................................................36  
5.2 Database Management and Quality Control .......................................................................36  
6 STATISTICAL METHODS............................................................................................37  
6.1 Statistical Methods............................................................................................................ ..37 
6.1.1 Population...............................................................................................................37  
6.1.2 Background and Demographic Characteristics ......................................................37  
6.1.3 Study Medication ...................................................................................................37  
6.1.4 Concomitant Therapy.............................................................................................37  
6.1.5 Efficacy Evaluation ................................................................................................37  
6.1.6 Safety Evaluation ...................................................................................................38  
6.1.7 Interim Analysis .....................................................................................................38  
6.1.8 Reports to the Adjudication Committees ...............................................................39  
6.2 Sample Size.................................................................................................................... .....39  
7 PROCEDURES AND INSTRUCTIONS........................................................................39  
7.1 Packaging, Labeling, Storage, and Return of Clinical Supplies .........................................39  
7.2 Drug Administration ...........................................................................................................3 9 
7.2.1 Dose Preparation ....................................................................................................39  
7.2.2 Dose Administration...............................................................................................40  
Savient Pharmaceuticals, Inc. Confidential Page 8 
Protocol M0401 FINAL  11 July 2011 KRYSTEXXA ® (pegloticase) 
 
8 REFERENCE LIST..........................................................................................................41  
APPENDIX 1: ADMINISTRATIVE PROCEDURES .................................................................... 43 
1. Changes to the Protocol ......................................................................................................43  
2. Monitoring Procedures........................................................................................................43  
3. Data Collection....................................................................................................................43  
4. Document Retention............................................................................................................4 4 
5. Disclosure and Confidentiality............................................................................................44  
6. Publication of Results ......................................................................................................... 45 
7. Discontinuation of Study.....................................................................................................45  
8. Changes in Study Personnel................................................................................................45  
APPENDIX 2: ETHICS AND GOOD CLINICAL PRACTICE .....................................................46  
1. Institutional Review Board/I ndependent Ethics Committee ...............................................46  
2. Informed Consent............................................................................................................... .47 
3. Compliance with Law, Audit, and Debarment....................................................................47  
4. Compliance with Financial Disclosure Requirements ........................................................48  
APPENDIX 3.  VISIT SCHEDULES AND ASSESSMENTS .......................................................49  
1.    Schedule of Pr ocedures and Evaluations.............................................................................49  
2.    Schedule of Procedures and Evalua tions for Patients in Follow-up after Early 
KRYSTEXXA Discontinuation ..................................................................................50  
3.    Serum Sample Collections for Specified Adverse Events...................................................51  
 
 
LIST OF TABLES 
Table 1 NIAID/FANN Clinical Crit eria for Diagnosing Anaphylaxis................................... 30 
 
 
LIST OF FIGURES 
Figure 1 Study Design.......................................................................................................... .... 20 
 
Savient Pharmaceuticals, Inc. Confidential Page 9 
Protocol M0401 FINAL  11 July 2011 KRYSTEXXA ® (pegloticase) 
 
LIST OF ABBREVIATIONS 
AE adverse event 
C3 complement component 3 
C4 complement component 4 
CRF case report form 
CRO Contract Research Organization 
eCRF Electronic case report form 
ELISA enzyme-linked immunosorbant assay 
FDA Food and Drug Administration 
G6PD glucose-6-phosphate dehydrogenase 
GCP Good Clinical Practice 
IC informed consent 
ICH International Conference on Harmonisation 
i.v. intravenous(ly) IR infusion reaction 
IRB Institutional Review Board 
ITT Intent to Treat 
kDa kilodalton MedDRA Medical Dictionary  for Regulatory Activities 
MMRM mixed-effect model repeated measure 
NIAID/FANN National Institute of Allergy and In fectious Disease/Food Allergy and 
Anaphylaxis Network 
NSAID non-steroidal anti-inflammatory drug 
PEG polyethylene glycol po [per os] by mouth 
PUA plasma uric acid SAE serious adverse event SAP statistical analysis plan 
Savient Savient Pharmaceuticals, Inc. 
SOP standard operating procedure 
SUA serum uric acid 
US United States 
Savient Pharmaceuticals, Inc. Confidential Page 10 
Protocol M0401 FINAL  11 July 2011 KRYSTEXXA ® (pegloticase) 
 
PROTOCOL SYNOPSIS 
Name of product  KRYSTEXXA ® (pegloticase) 
Drug substance: Pegloticase is a uric acid-specific en zyme which is a polyethylene-glycol 
conjugated (PEGylated) product that c onsists of recombinant, modified, 
mammalian urate oxidase (uricase) pr oduced by a genetically modified 
strain of Escherichia coli . Uricase is covale ntly conjugated to 
monomethoxypoly(ethylene glycol) (mPE G; 10 kDa molecular weight). 
The cDNA coding for uricase is based on mammalian sequences. Each 
uricase subunit has a molecular weig ht of approximately 34 kilodaltons 
(kDa). The average molecular weight of pegloticase (tetrameric enzyme conjugated to a mean of 10.2 mPEG molecules) is approximately 540 
kDa. 
Protocol number: M0401 
Study title: Observational study of the use of KRYSTEXXA ® (pegloticase) in adult 
hyperuricemic patients with gout re fractory to conventional therapy 
Phase: 4 
Objectives: Primary
: 
To evaluate the frequency and seve rity of infusion reactions (IRs), 
anaphylaxis, and immune complex-related events. 
Secondary:  
To identify serious adverse events (SAEs) associated with KRYSTEXXA 
therapy. 
To further evaluate the efficacy of KRYSTEXXA in this patient 
population of adult hyperuricemic patients with gout refractory to conventional therapy. 
Study design: This is a multicenter, open-lab el, single-arm observational study. 
Investigational 
plan: Approximately 1500 patients will be enrolled in order to observe 
treatment of up to 500 patients for a duration of 1 year. Patients who 
discontinue treatment before 51 week s will be asked to remain in the 
study for follow-up assessments for the remainder of their planned 
treatment duration. 
 The number of patients to  be enrolled will be 
reassessed approximately 2 years afte r the first patient is enrolled. The 
study will be conducted at approximately 300 centers in the United States (US). It is estimated that approxi mately 2.5 years will be required for 
recruitment, from the first to the last patient's screening visit. 
Savient Pharmaceuticals, Inc. Confidential Page 11 
Protocol M0401 FINAL  11 July 2011 KRYSTEXXA ® (pegloticase) 
 
Treatment: Patients eligible for initial tr eatment with KRYSTEXXA 8 mg by 
intravenous (i.v.) infusion every 2 w eeks will be offered enrollment into 
the observational study for a year. Seru m uric acid (SUA) levels will be 
monitored prior to infusion and therapy will be discontinued if levels 
increase above 6 mg/dL on two consecutive measurements.  If the SUA is noted to be above 6 mg/dl the sponsor  suggests that a repeat SUA should 
be drawn when the result is noted to  confirm, and if the 2 consecutive 
levels are noted to be above 6 mg/dL then it is advised to discontinue 
therapy. 
Study duration: Approximately 63 weeks, including 51 weeks of treatment and 12 weeks 
of follow-up. 
• Selection criteria Inclusion criteria:
 
• Adult patients (age ≥ 18 years) with chr onic gout refractory to 
conventional therapy, defined as pa tients who have failed to normalize 
SUA and whose signs and symptoms are inadequately controlled with 
xanthine oxidase inhibitors at the maximum medically appropriate 
dose, or for whom these drugs are contraindicated. 
• Patients who have made the deci sion, along with their treating 
physician, to begin treatment with KRYSTEXXA. 
• Patients who are willing and able to give informed consent and adhere 
to visit/protocol schedules (informed consent must be given before the first study procedure is performed). 
Exclusion criteria:
 
• Glucose-6-phosphate dehydrogenase (G6PD) deficiency 
• Non-compensated congestive heart failure 
• Pregnancy or breast feeding 
• Prior treatment with pegloticase or another recombinant uricase 
• Known allergy to urate oxidase 
• Prior treatment or concomitant ther apy with a polyethylene glycol 
(PEG)-conjugated drug 
• Recipient of an inves tigational drug within 4 weeks prior to study drug 
administration or plans to take an  investigational agent during the 
study 
Investigational drug: None  
Reference therapy: KRYSTEXXA ® (pegloticase) 8 mg i.v. every 2 weeks 
Savient Pharmaceuticals, Inc. Confidential Page 12 
Protocol M0401 FINAL  11 July 2011 KRYSTEXXA ® (pegloticase) 
 
Efficacy criteria: Normalization of SUA to < 6 mg/dL 
Decrease in the number of swollen join ts and the number of tender joints 
Decrease in the frequency of gout flares Reduction in the number of tophi  
Safety criteria: IRs, anaphylaxis, and immune comple x-related adverse events, serious 
adverse events and adverse even t profile, including gout flares 
Statistical methods: Descriptive statistics will be empl oyed to summarize the proportion of 
responders, where a responder is define d as a patient whose SUA values 
were < 6 mg/dL at their final 2 co nsecutive study visits. Descriptive 
statistics will be provided for th e number of swollen joints and tender 
joints at baseline, 6 months and 12 months or Early Di scontinuation; for 
changes in numbers of gout flares ba sed on patient reported history at 6-
week intervals for Months 1-3 and 3- month intervals thereafter; and for 
change in the number of tophi at 6 months (Visit 13) and 12 months 
(Visit 26) or Early Discontinuation.  
It is anticipated that there may be a considerable number of study patients 
who will drop out of the study. The s ponsor will make every effort to 
identify the reason(s) for dropout be fore reaching the primary safety 
endpoint. For the analysis of each efficacy endpoint, various sensitivity 
analyses will be performed under different assumptions of potentially informative dropouts. For continuous efficacy variables, sensitivity 
analyses will be performed using standard mixed-effect model repeated measure (MMRM) methods. All the analyses will be summarized using 95% confidence interval estimates. Th e resulting summarized statistics 
for efficacy will be compared to those reported from the pre-approval phase 3 studies. 
Adverse events will be summarized by presenting the proportion of 
patients having any adverse event (AE), overall and by body system, and 
by event as defined by the Medical Di ctionary for Regulatory Activities 
(MedDRA) preferred term. Separate su mmary tables will  be provided for 
IRs, anaphylaxis AEs, and immune complex-related AEs.  
For each type of the primary safety endpoints, one event, at most, will be 
counted per patient. The 95% (exact) confidence interval estimates for 
each type of safety endpoint will be reported for the rate of incidence both at the administrative interim analysis, for evaluating the feasibility of the study, and at the final analysis. The following hypothesis will be 
specifically tested: the rate of IRs seen in the phase 3 studies will be 
reduced in this study by monitori ng SUA prior to infusions and 
Savient Pharmaceuticals, Inc. Confidential Page 13 
Protocol M0401 FINAL  11 July 2011 KRYSTEXXA ® (pegloticase) 
 
discontinuing therapy in patients if levels increase to above 6 mg/dL, 
particularly when 2 consecutive leve ls above 6 mg/dL are observed. With 
at least 500 patients enrolled with  1 year follow-up, the power of 
detecting a 26% IR rate (the observed value from the pre-approval phase 
3 studies) against 13% is at least 90%. The rate of IRs reported during the 
study will be reported and compared descriptively to the rates observed in the pre-approval phase 3 studies.  
 
 There is no planned interim analysis . However, the number of enrolled 
patients will be reassessed approximately  2 years after the first patient is 
enrolled. This data will be utilized to make a prediction concerning the 
future enrollment profile. The enrollm ent goal may be adjusted depending 
on the drop-out rate such that approximately 500 patients will complete the 1 year treatment period. 
Savient Pharmaceuticals, Inc. Confidential Page 14 
Protocol M0401 FINAL  11 July 2011 KRYSTEXXA ® (pegloticase) 
 
 
Assessments: Baseline samples for iden tification of antibodies to pegloticase and to 
PEG, and determination of co mplement markers (complement 
component 3 [C3] and complement  component 4 [C4]) and tryptase 
levels. Antibody samples at End-of-St udy and at 3-month intervals during 
follow-up after discontinuation of treatment. 
Review of concurrent medications, co-morbidities, and compliance with 
premedication regimes for gout flares.  
Determination of SUA before each infusion. Recording of drug, dose and timing of IR prophylactic medications. Recording of infusion start and finish times, sodium chloride diluent used 
and the total volume infused. Swollen joint and tender joint counts, and number of  tophi to be assessed 
at baseline, 6 months (Visit 13) and 12 months (Visit 26) or Early 
Discontinuation. Flares:
 
• At baseline, document the history of  gout flares from the previous 
6 months 
• Documentation of the occurrence and duration of any gout flares 
experienced while the patient is participating in the study 
IRs and anaphylaxis:  
• Documentation of signs and symp toms and onset time in relation 
to the initiation of the KRYSTE XXA infusion, and treatment, if 
any 
• Follow-up laboratory assessments ma y include the collection of 
samples for analysis of antibodies to pegloticase and PEG, anti-
pegloticase IgE, C3, C 4, and tryptase levels. 
 Immune complex disease:  
• Clinical investigation of a presumptive immune complex disease (as per clinical practice) and of  complement markers (C3, C4) will 
be pursued. 
Savient Pharmaceuticals, Inc. Confidential Page 16 
Protocol M0401 FINAL  11 July 2011 KRYSTEXXA ® (pegloticase) 
 
1 INTRODUCTION 
1.1 Disease Background 
Gout is a disease resulting from the body’s infla mmatory response to urate crystals that deposit 
in tissues and joint sp aces in susceptible indi viduals with chronic hype ruricemia (Dalbeth and 
Haskard, 2005). Uric acid, the end metabolite of purine metabolism in humans, is poorly soluble 
in serum at concentrations above 6.8 mg/dL. Mo st mammals, with the exception of humans, have 
an endogenous intracellular hepatic uricase that converts uric ac id into allantoin, a highly soluble 
and easily excreted end metabolite (Wu et al, 1992). Uric acid production and excretion are 
normally balanced in the human body, maintainin g a serum concentration below the limit of 
urate solubility. However, this balance may be disturbed by decreased excretion, overproduction, or a combination of these factors leading to hyperuricemia (Kanellis et al, 2006). Hyperuricemia 
itself is not associated with symptoms or signs of disease but in the context of gout, prolonged 
hyperuricemia leads to pr ecipitation of monosodium urate crysta ls in and around joints and other 
tissues and the evolution of defining clinical manifestations. The hallmark symptoms of gout are related to acute inflammatory monoarticular arth ritis, lasting days or weeks and causing exquisite 
pain, i.e., an acute gout flare. Protracted hyperuricemia may lead not only to freque nt gout flares, 
but may result in urate nephropathy and renal calcu li, and gout tophi (no dular deposits of urate 
crystals and inflammatory cells) in joints, soft tissues, bone s, and in some organs. The 
cornerstone of gout therapy is treatment of hype ruricemia with urate-lo wering drugs (Becker and 
Jolly, 2005). 
Refractory gout occurs in a subset of symptoma tic gout patients whose hyperuricemia cannot be 
controlled with conventional xanthi ne oxidase inhibitors at the maxiumum medically appropriate 
dose. The hyperuricemia of most gout patients ca n be controlled successfully with a xanthine 
oxidase inhibitor (e.g., allopurinol ) to reduce uric acid formation or agents such as probenecid 
that promote uric acid excretion (uricosuric dr ugs). Although failure of pa tient compliance in the 
daily use of allopurinol or uricos uric drugs is often the root cause of treatment failure (Stamp et 
al, 2000), allopurinol ther apy at a maximum medically appropri ate dose is sometimes ineffective 
in normalizing the serum uric acid (SUA), or may be contraindicated in patients with impaired 
renal function or in patients with allopurinol hyper sensitivity (Hande et  al, 1984; Singer and 
Wallace, 1986; and Arellano and Sacristan, 1993) . Uncontrolled or inadequately controlled 
hyperuricemia leads to in creasing frequency and severity of  gout-related symptoms and chronic 
disease, e.g., gout flares, tophi , gouty arthritis, and urate nephr opathy. Chronic gout may lead to 
joint destruction and disability. For these individu als, no effective therapies have been available 
to normalize the circulating uric acid as a mean s of slowing or revers ing the progress of the 
disease. 
1.2 KRYSTEXXA Background 
KRYSTEXXA ® (pegloticase) is indicated for the trea tment of chronic gout  in adult patients 
refractory to conventional ther apy. KRYSTEXXA is a uric acid- specific enzyme which is a 
Savient Pharmaceuticals, Inc. Confidential Page 17 
Protocol M0401 FINAL  11 July 2011 KRYSTEXXA ® (pegloticase) 
 
polyethylene glycol -conjugated (PEGylated) product that consists  of recombinant, modified, 
mammalian urate oxidase (uricase) produced by a genetically modified strain of Escherichia 
coli. Uricase is covalently conjugated to m onomethoxypoly(ethylene glycol) (mPEG; 10 kDa 
molecular weight). KRYSTEXXA ach ieves its therapeutic affect by catalyzing the oxidation of 
uric acid to the much more soluble allantoi n, thereby lowering SUA with allantoin readily 
eliminated, primarily by renal excretion. 
Additional background concerning KRYSTEXXA can be found in the current version of the 
Food and Drug Administration (FDA)-approved  KRYSTEXXA Full Prescribing Information. 
1.2.1 Efficacy Assessments in Clinical Studies of KRYSTEXXA 
The safety and efficacy of KRYSTEXXA ® (pegloticase) has been evaluated in 7 clinical studies, 
including 2 replicate, multicenter, randomi zed double-blind, placebo-controlled studies of 
6-month duration. In the two placebo-controlled  studies, adult patients with chronic gout 
refractory to conventional therapy were randomized  to receive intravenous (i.v.) infusions of 
KRYSTEXXA 8 mg every 2 weeks or every 4 weeks or placebo in a 2:2:1 ratio. All patients also received prophylaxis for infusion reactions (IRs) and for gout flares. To assess the efficacy of KRYSTEXXA in lowering uric acid, the primary e ndpoint in both trials was the proportion of 
patients who achieved plasma uric acid (PUA) less than 6 mg/dL for at least 80% of the time during Month 3 and Month 6. A greater proportio n of patients treated with KRYSTEXXA every 
2 weeks achieved urate lowering to below 6 mg/dL than patients receivin g placebo (38% to 47% 
of patients receiving KRYSTEXXA vs. 0% of patient s receiving placebo). In addition, at Month 
6, the percentage of patients who achieved a complete resolution of tophi (defined as 100% 
resolution of at least 1 target tophus, the appearance of no new tophi, and no single tophus 
showed progression) was 45%, 26% and 8%  with KRYSTEXXA 8 mg every 2 weeks, 
KRYSTEXXA 8 mg every 4 weeks, and placebo, respectively. Although the 4 week regimen also demonstrated efficacy for the primary e ndpoint, this regimen was associated with an 
increased frequency of IRs and was less efficacious with respect to tophi. Therefore, pegloticase 
8 mg every 2 weeks was approved by the US FDA on September 14, 2010 for the treatment of 
adult patients with chronic gout re fractory to conventional therapy.
 
1.2.2 Safety Assessments in Clin ical Studies of KRYSTEXXA 
The most commonly reported serious adverse re actions from the pre-marketing controlled 
clinical trials in patients tr eated with KRYSTEXXA 8 mg every 2 weeks were gout flare, IR, and 
anaphylaxis.  
Gout flares were more frequent during th e first 3 months of treatment (74% in 
KRYSTEXXA-treated patients vs. 51%  in placebo-treated patients) , and seemed to decrease 
over the next 3 months (41% KRYSTEXXA vs. 67% placebo). An increase in gout flares is 
frequently observed upon initiation of anti-hype ruremic therapy. Thus, all patients in these 
studies received non-steroidal anti -inflammatory drugs (NSAID) or co lchicine or both for at least 
7 days as gout flare prophylaxis before be ginning KRYSTEXXA; patient s continued on this 
regimen for the 6-month treatment duration. 
Savient Pharmaceuticals, Inc. Confidential Page 18 
Protocol M0401 FINAL  11 July 2011 KRYSTEXXA ® (pegloticase) 
 
All patients in Phase 3 clinical trials were pre- treated with an oral antihistamine (fexofenadine, 
60 mg by mouth [po], the night before and morni ng of the infusion), i.v. corticosteroid (200 mg 
hydrocortisone i.v.) and acetaminophen (1000 mg po) before the infusion to prevent anaphylaxis 
and IRs. Nevertheless, IRs were reported in  26% of patients treated with KRYSTEXXA 8 mg 
every 2 weeks compared to 5% of patients treated with placebo. Manifestations of IRs included urticaria, dyspnea, ches t discomfort, chest pain, erythema, and pruritus. Approximately 3% of 
IRs occurred with the first dose, and most (91%) occurred during the infusion rather than after it 
was completed. 
None of the IRs which occurred in the pegloticase studies was ca tegorized as anaphylaxis by the 
investigators who enrolled subjects in the Phase 2, Phase 3, or open-label extension studies. The 
US FDA performed a retrospective analysis of th e IRs to assess for anaphylaxis, using modified 
National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network 
(NIAID/FAAN) diagnostic criteria (Sampson et al , 2006). Using their analysis, the frequency of 
anaphylaxis was 6.5% in all patients treated with KRYSTEX XA 8 mg every 2 week. During 
randomized, placebo-controlled studies, the freq uency was 5% compared to none with placebo. 
An independent immunologist commissioned by the sponsor to review the data based strictly 
upon the NIAID/FAAN clinical  criteria for anaphylaxis determined the overall rate in the clinical 
studies to be 2.4%. 
A retrospective analysis of the data from the Phas e 3 trials revealed that  most IRs occurred when 
uric acid values were above 6 mg/dL. Important ly, other than one case th at met the criteria for 
anaphylaxis occurring duri ng the first dose of pegloticase (8 mg), all other cases that met the 
criteria for anaphylaxis occurred when a subject’ s last uric acid value was above 6 mg/dL. Thus, 
the monitoring rule was developed and incorpor ated into the FDA-a pproved Full Prescribing 
Information: “Monitor serum uric acid levels pr ior to infusions and consider discontinuing treatment if levels 
increase to above 6 mg/dL, part icularly when 2 consecutive le vels above 6 mg/dL are observed.”   
Other non-serious AEs reported in ≥ 5% of patients treated with KRYSTEXXA 8 mg every 
2 weeks included nausea (12%), contusion or  ecchymosis (11%), nasopharyngitis (7%), 
constipation (6%), chest pain  (6%) and vomiting (5%). 
Anti-pegloticase antibodies de veloped in 92% of patients treated with KRYSTEXXA. High 
anti-pegloticase antibody titers (> 1:2430) were associated with both a failure to maintain 
pegloticase-induced normalization of uric acid a nd a higher incidence of IRs. Because of this 
high rate of antibody development, one of the sp ecific safety endpoints in  the larger population 
for the current study will be to determine if there is a risk of immune complex disease in patients 
treated with KRYSTEXXA. No cases of immune  complex disease were identified in the 
pre-marketing controlle d clinical studies. 
While KRYSTEXXA has not been formally studie d in patients with congestive heart failure, 
there were some patients who experienced exa cerbation during the clinic al studies. It was 
Savient Pharmaceuticals, Inc. Confidential Page 19 
Protocol M0401 FINAL  11 July 2011 KRYSTEXXA ® (pegloticase) 
 
therefore recommended that treating physicians  exercise caution when using KRYSTEXXA in 
patients who have congestive heart failure and to monitor patients closely following infusion. 
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a contrai ndication for KRYSTEXXA 
due to the risk of hemolysis and methemoglobinemia in these patients. Therefore, all patients in 
this study must be screened for this enzyme deficiency. 
Refer to the current version of the FDA-a pproved KRYSTEXXA Full Pres cribing Information 
and Pegloticase Investigators Broc hure for detailed information concerning the safety profile of 
KRYSTEXXA. 
1.3 Study Rationale 
This Phase 4, observational study is primarily focused on evaluating the frequency and severity 
of IRs, anaphylaxis, and imm une complex-related AEs in a dult patients with chronic gout 
refractory to conventional therapy who are being treated with KRYSTEXXA. In the post-
approval setting, this study also provides a means of identifying and assessing any SAEs 
associated with KRYSTEXXA therapy. The effi cacy of KRYSTEXXA, in terms of normalizing 
SUA and decreasing the number of swollen joints and tender jo ints, reducing gout flares, and 
resolving tophi in this patient population can al so be further evaluate d in a large population 
within the standard healthcare setting. 
2 STUDY OBJECTIVES 
2.1 Primary  
The primary objective of the study is to evaluate the frequency and severity of IRs, anaphylaxis, 
and immune complex-related events. 2.2 Secondary  
Secondary objectives are to identify SAEs asso ciated with KRYSTEXXA therapy and to further 
evaluate the efficacy of KRYSTEXXA in this pa tient population of adult hyperuricemic patients 
with gout refractory to  conventional therapy.
 
3 INVESTIGATIONAL PLAN 
3.1 Overall Study Design 
This is a Phase 4, multicenter,  open-label, single-arm observational study of KRYSTEXXA 8 mg 
i.v. every 2 weeks in adult hyperu ricemic patients with gout refr actory to conventional therapy. 
Approximately 1500 patients will be enrolled in order to observe treatment of up to 500 patients 
at approximately 300 centers in  the United States (US). Stud y duration is approximately 63 
weeks, including 51 weeks of treatment and 12 weeks of follow-up. Patients who discontinue 
treatment before 51 weeks (i.e., before all 26 planned KRYSTEXXA infusions) will be asked to 
remain in the study for follow-up assessments fo r the remainder of their planned treatment 
duration. It is estimated that a pproximately 2.5 years will be requi red for recruitment, from the 
Savient Pharmaceuticals, Inc. Confidential Page 21 
Protocol M0401 FINAL  11 July 2011 KRYSTEXXA ® (pegloticase) 
 
• IRs will be defined as any AE or cluster of AEs, not attributable to another cause, that 
occurs during or within 2 hours after the infusion of KRYSTEXXA. Other cases that 
occur outside of the 2-hour window may also be  categorized as an IR as per investigator 
discretion. 
• Anaphylaxis will be defined using the NIAID/FANN criteria (Sampson et al, 2006), 
comprised of involvement of the skin or  mucosal tissue and either respiratory 
compromise or reduced blood pressure or as sociated symptoms of end-organ dysfunction 
(refer to Table 1). Mast cell involvement in any constellation of signs and symptoms will 
be evaluated by measuri ng serum tryptase levels. 
• Immune complex-related AEs will be defined as any presumptive immune 
complex-related disorders that are confirme d by an appropriate investigation of the 
disease and of complement markers (com plement component 3 [C3], complement 
component 4 [C4]). Clinical manifestations co uld include skin rash, arthralgia, arthritis, 
and proteinuria (see Section 3.8.1.3). 
The proposed patient number (approximately 1500 enrolled patients in order to observe 
treatment of up to 500 patients fo r a duration of 1 year) and 1-y ear duration of the study will 
significantly extend the patient exposure to KRYSTEXXA compared with the pre-marketing 
controlled clinical trials.  
In addition, post-hoc analyses of  the clinical study data dem onstrated that if KRYSTEXXA had 
been stopped when a patient’s uric acid level rose  to greater than 6 mg/dL at 2 consecutive visits, 
the incidence of IRs would have been reduced by half and there would have been little change in 
the efficacy outcome. Current guidance for the use of KRYSTEXXA thus recommends 
monitoring SUA levels prior to infusions and co nsidering discontinuing treatment if SUA levels 
increase to above 6 mg/dL, part icularly when 2 consecutive le vels above 6 mg/dL are observed. 
This study will follow this guidance and provides for the collection of data on both SUA levels 
and IRs to extend the knowledge base regard ing the relationship between these factors. 
The design of this study follows the FDA-approved Full Prescribing Information for the use of 
KRYSTEXXA and allows for capturing additional data related to the safety and efficacy of KRYSTEXXA within the standard healthcare se tting. Efforts have been made to limit 
study-specific activities for the enrolled patients and participating healthcar e providers while still 
allowing for a robust assessment of key safety and efficacy features of KRYSTEXXA treatment 
in this patient population.  
3.3 Study Population 
3.3.1 Patient Population 
The patient population in this study will be hyperuricemic (SUA > 6 mg/dL) adult men and 
women (age ≥  18) diagnosed with chronic gout and w ho are refractory to conventional therapy. 
Gout refractory to conventional therapy occurs in patients who have failed to normalize SUA and 
whose signs and symptoms are inadequately contro lled with xanthine oxid ase inhibitors at the 
Savient Pharmaceuticals, Inc. Confidential Page 22 
Protocol M0401 FINAL  11 July 2011 KRYSTEXXA ® (pegloticase) 
 
maximum medically appropriate dos e or for whom these drugs are contraindicated. To enter this 
study, the patient and the physician must have decided to begin treatment with KRYSTEXXA. 
The sample size for the study will be approximate ly 500 patients treated for one year. This 
sample size is a pragmatic one that will allow enough patients to enroll in a suitable time period 
for evaluation of the frequency and severity of  IRs, anaphylaxis and immune complex-related 
AEs and to identify SAEs associated with KRYSTEXXA therapy in this post-approval, 
observational study.  
3.3.2 Inclusion and Exclusion Criteria 
3.3.2.1 Inclusion Criteria 
Patients are eligible for the study if all of the following apply: 
• Adult patients (age ≥ 18 years) with chronic gout refract ory to conventional therapy, defined 
as patients who have failed to normaliz e SUA and whose signs and symptoms are 
inadequately controlled with xanthine oxidase inhibitors  at the maximum medically 
appropriate dose, or for whom these drugs are contraindicated. 
• Patients who have made the decision, along with  their treating physicia n, to begin treatment 
with KRYSTEXXA. 
• Patients who are willing and able to give info rmed consent and adhere  to visit/protocol 
schedules (informed consent must be given be fore the first study procedure is performed). 
3.3.2.2 Exclusion Criteria 
Patients will be excluded from participation in the study if any of the following apply: 
• Glucose-6-phosphate dehydrogenase (G6PD) deficiency 
• Non-compensated congestive heart failure 
• Pregnancy or breast feeding 
• Prior treatment with pegloticase or another recombinant uricase 
• Known allergy to urate oxidase 
• Prior treatment or concomitant therapy with  a polyethylene glyc ol (PEG)-conjugated drug 
• Recipient of an inves tigational drug within 4 weeks prior to study drug administration or 
plans to take an investigational agent during the study 
3.4 Treatments 
3.4.1 Investigational Drug and Reference Therapy 
3.4.1.1 Investigational Drug 
No investigational drug will be utilized in this post-market, observational study. 
Savient Pharmaceuticals, Inc. Confidential Page 23 
Protocol M0401 FINAL  11 July 2011 KRYSTEXXA ® (pegloticase) 
 
3.4.1.2 Reference therapy 
KRYSTEXXA is commercially availa ble in the US as a sterile, clear, colorless solution 
containing 8 mg/mL pegloticase in phosphate-buffered saline. KRYSTEXXA ® (pegloticase) 
concentrations are expressed as concentrations  of uricase protein. Each mL of KRYSTEXXA 
contains 8 mg of uricase pr otein conjugated to 24 mg of  10 kDa monomethoxypoly(ethylene 
glycol) (mPEG). Excipients include disodium  hydrogen phosphate dihydrate, sodium chloride, 
sodium dihydrogen phosphate dihydra te and water for injection.  
KRYSTEXXA is supplied in a singl e-use, 2 mL glass vial with  a Teflon coated (latex-free) 
rubber injection stopper to deliver KRYSTEXXA as 8 mg of uricase protein in 1 mL volume for 
i.v. infusion. Before preparation for use, KRYSTEXXA should be stored in the carton, 
maintained under refrigeration between 2ºC and 8º C (36ºF and 46ºF), prot ected from light and 
should not be shaken or frozen. 
3.4.2 Treatment Assignment 
All patients will receive KRYSTEXXA 8 mg  by i.v. infusion every 2 weeks. 
3.4.3 Blinding 
This is an open-label study. 3.4.4 Treatment Compliance 
All doses of KRYSTEXXA will be administered in a healthcare setting by healthcare 
professionals. The number of doses and amount of each dose received by each patient will be 
captured in the patient’s medical record and in th e case report form (CRF)/electronic case report 
form (eCRF).  
3.4.5 Concomitant Therapy 
Pharmaceutical agents specifically indicated fo r lowering SUA (e.g., allopurinol) should not be 
used in conjunction with KRYSTEXXA. KRYSTEXXA  is indicated for use in patients with 
chronic gout whose signs and symptoms are inade quately controlled with  conventional therapy 
(i.e., xanthine oxidase inhibitors  such as allopurinol). If a patient is being followed after 
discontinuation of KRYSTEXXA (see Section 3.5.3), another urate-lowering drug may be 
instituted at any time. 
All medications taken for concurrent medical conditions and any required analgesics must be 
recorded in patients’ medical records and in  the CRF/eCRF.  Data captured on the use of 
concomitant medications will include the name of the drug, and if known, the start date, stop 
date and indication. 
The use of all other investigational dr ugs is prohibited throughout the study. 
3.5 Visit Schedules and Assessments 
The schedule of visits and assessm ents can be found in Appendix 3. 
Savient Pharmaceuticals, Inc. Confidential Page 24 
Protocol M0401 FINAL  11 July 2011 KRYSTEXXA ® (pegloticase) 
 
3.5.1 Screening Procedures 
Prior to entry into the protocol , the nature and risks of the study must be reviewed with each 
patient. Each patient or each patient’s legal repr esentative must be given the opportunity to read 
the Institutional Review Board’ s (IRB) approved informed consen t (IC) form and ask questions. 
After all questions raised by a potential participant are answered, and before any 
protocol-specified screening procedures are in itiated, each patient or each patient’s legal 
representative must sign and date the consent fo rm. A copy of the signed and dated IC form must 
be provided to the patient. 
After IC is obtained, a 6-digit patient number will be assigned. The first three digits of each 
patient number will represent the site and the last  three will be unique for each patient at each 
site. Potential patients will be screened to determine if they satisfy all inclusion and exclusion 
criteria. All screening procedures must be co mpleted prior to dosing. Specified CRF/eCRF pages 
to report basic demographic information and reason(s) for exclusion must be completed for all patients who signed an informed consent form, but never received KRYSTEXXA.  
The following evaluations will be performed on each patient and results recorded in the medical 
record and CRF/eCRF: 
• Informed consent (process must be documented in the medical record)  
• Medical history – include all clinically si gnificant medical problems within the past 
5 years, but excluding gout history which will be separately documented  
• Gout history and symptom severity  
o Documentation of the contrai ndication to or the failure of conventional therapy at 
the maximum medically appropriate dose  
o Number of gout flares in the last 6 months, and most recent occurrence  
o Assessment of tophi and gouty arthritis, in cluding a count of the total number of 
palpable subcutaneous  and subperiosteal tophi, if accessible  
o The number of tender join ts and swollen joints  
o Documentation of the history of gout-related kidney disease  
• Physical examination (including but not limite d to dermatological, head and neck, chest 
and cardiac, abdominal, musculoskeleta l, and nervous system examination)  
• Vital signs and height and body weight  
• Obtain a blood sample for analysis of SUA  
• Obtain a blood sample for G6PD testing  
Savient Pharmaceuticals, Inc. Confidential Page 25 
Protocol M0401 FINAL  11 July 2011 KRYSTEXXA ® (pegloticase) 
 
• Review concomitant medications  
• Initiate gout flare prophylaxis and advise patient to contac t site within 12 hours of gout 
flare symptom onset. If prophylaxis is  contraindicated, document the reason.  
• Advise patient of the IR prophylaxis regi men to be used before each scheduled 
KRYSTEXXA infusion.  
3.5.2 Study Procedures  
3.5.2.1 Visits 1 through 26 
At each visit, the following procedures must be completed before administration of 
KRYSTEXXA : 
• Provide the KRYSTEXXA Medication Guide and answer any questions the patient has. 
• Review concomitant medications, and question patient about any new medical 
conditions.  
• Record all new clinically significant medical conditions in both the medical record and 
on the adverse event CRF/eCRF and evaluate for the occurrence of an acute gout flare 
since the previous visit.  
• After the first visit, serum uric acid (SUA) levels will be monitored prior to the next infusion and therapy will be discontinued if levels increase above 6 mg/dL on two 
consecutive measurements.  If the SUA is noted  to be above 6 mg/dl the sponsor suggests 
that a repeat SUA should be drawn when the result is noted to confirm, and if the 2 
consecutive levels are noted to be above 6 mg/dL then it  is advised to discontinue 
therapy.
 
• Record blood pressure, heart rate, respirator y rate and temperature shortly before study 
drug infusion. 
• If patient has not had SUA analyzed between hi s/her last visit and th e current one, obtain 
blood samples for analysis of SUA.  
• Record self-administered pre-medications the patient took for prophylaxis against infusion reactions, and administer  hydrocortisone (see Section 3.5.8). Record the drug 
name, dose, route and time of administration of each medication. 
At Visit 1 , but not routinely for other vi sits, also obtain blood sample s for baseline determination 
of complement components (C3, C4), tryptase  level, and identifica tion of antibodies to 
pegloticase or PEG. These baseline samples will be stored for later analysis to compare with 
blood samples that are collected at subsequent visits to assess th ese parameters as part of the 
evaluation of an IR or potential immu ne-complex related event (see Section 3.5.8.3). 
Savient Pharmaceuticals, Inc. Confidential Page 26 
Protocol M0401 FINAL  11 July 2011 KRYSTEXXA ® (pegloticase) 
 
Following completion of the above procedures: 
• Administer KRYSTEXXA (admixed in 250 mL 0.45% or 0.9% Sodium Chloride 
Injection, USP) by i.v. infusion over 120 minutes . Record the infusion start and finish 
times, and total volume infused. Details  regarding study drug preparation and 
administration can be found in Section 7.2 and are described in the FDA-approved 
KRYSTEXXA Full Prescribing Information. 
• Follow standard procedures at the center at  which the infusion is being performed to 
monitor for IRs. 
• Monitor for AEs during the infusion. See Section 3.5.8 for management and 
documentation of possible infusion-related reactions. 
• Patients may be discharged after an appr opriate period of time for post-infusion 
observation (approximately 1 hour after completion  of the infusion is recommended). 
• Monitor therapy by providing the patient with a laboratory slip  and advising him/her to 
have blood drawn for analysis of S UA prior to the next dosing visit. 
3.5.2.2 Visits 13 and 26 
In addition to the study procedures listed for Visits 1 through 26, the following assessments will 
also be collected at 6 months (Visit 13) and 12 months (Visit 26) after in itiating treatment with 
KRYSTEXXA: 
• Perform swollen joint and tender joint counts 
• Perform a count of the total number of palpab le subcutaneous and subperiosteal tophi, if 
accessible  
3.5.2.3 Visit 27: End of Study  
The final procedures at End of Study (Visit 27) (12 weeks after final KRYSTEXXA infusion) 
will include: 
• Inquire and assess for AEs, gout flares and changes in concomitant medications since 
previous study visit 
• Complete physical exam, reviewing same  body systems as at screening visit  
• Measure blood pressure, h eart rate and temperature  
• Collect blood samples for identification of antibodies to pegloticase or PEG  
• Record SUA results obtained after the last infusion  
• Instruct patients on post-study anti-h yperuricemic therapy as appropriate 
3.5.3 Early Treatment  Discontinuation Procedures 
Patients in whom KRYSTEXXA is discontinued be fore Visit 26 will be asked to continue in 
follow-up for the full duration of the study. In this  case, patients are to return 4 weeks (+/- 5 
Savient Pharmaceuticals, Inc. Confidential Page 27 
Protocol M0401 FINAL  11 July 2011 KRYSTEXXA ® (pegloticase) 
 
days) after their final infusion of KRYSTEX XA in order to undergo early treatment 
discontinuation study procedures.  Patients who discontinue treatment before 51 weeks (i.e., 
before all 26 planned KRYSTEXXA infusions) will be asked to remain in the study for follow-
up assessments for the remainder of their planne d treatment duration. These procedures include 
essentially the same procedures as Visit 26, adding only the final instruction to patients: 
• Inquire and assess for AEs, gout flares and changes in concomitant medications since 
previous study visit  
• Determine and record the reason for th e early discontinuation of  KRYSTEXXA  
• Complete physical exam, reviewing same  body systems as at screening visit  
• Measure blood pressure, heart rate and temperature 
• Collect blood samples for antibodies to pegloticase or PEG  
• Perform swollen joint and tender joint count 
• Perform a count of the total number of palpab le subcutaneous and subperiosteal tophi, if 
accessible  
• Instruct patients on post-KRYSTEXXA  anti- hyperuricemic therapy as appropriate 
 
Additional Follow-up Visit Procedures  
The first follow-up visit will be 3 months ( 12 weeks) after the last  KRYSTEXXA infusion, and 
at 3-month intervals subsequently.  Follow-up visits will only be  conducted for the remainder of 
the patient’s planned 1 year of study participa tion.  For example, subjects who discontinue 
treatment on or after Visit 19 would only have an Early Treatment Discontinuation Visit (at 4 
weeks after discontinuation) and a 3-m onth post-treatment follow-up visit.)  
Assessments during the post-treat ment follow-up period will include: 
• Inquire and assess for AEs, gout flares and changes in concurrent medications since 
previous study visit 
• Collect blood samples for identification of antibodies to pegloticase or PEG  
3.5.4 Early Discontinuation from the Study  
Patients who completely discontinue their partic ipation in the study and do not consent to be 
followed for the full year are to return 4 weeks (+/- 5 days) after their final infusion of 
KRYSTEXXA in order to undergo ea rly discontinuation study procedures.  These procedures 
include essentially the same procedures as Visit 26, but  without SUA and adding only blood 
samples for antibodies and the final instruction to patients: 
• Inquire and assess for AEs, gout flares and changes in concomitant medications since 
previous study visit  
• Determine and record the reason for th e early discontinuation of the patient  
Savient Pharmaceuticals, Inc. Confidential Page 28 
Protocol M0401 FINAL  11 July 2011 KRYSTEXXA ® (pegloticase) 
 
• Complete physical exam, reviewing same  body systems as at screening visit  
• Measure blood pressure, h eart rate and temperature  
• Collect blood samples for antibodies to pegloticase or PEG  
• Perform swollen joint and tender joint count 
• Perform a count of the total number of palpab le subcutaneous and subperiosteal tophi, if 
accessible  
• Instruct patients on post-study anti-h yperuricemic therapy as appropriate 
3.5.5 Interruption of Treatment 
Dosing with KRYSTEXXA may be de layed or interrupted for example, for vacation or for 
intercurrent illness, without requ iring a patient to be discontinued from the study. The reason for 
the delay or interruption will be captured in bo th the medical record and the CRF/eCRF. If the 
SUA is >6 mg/dL after an interruption in treatment, the patient may still resume treatment.  
3.5.6 Patient Discontinuation from Study 
Patients may be discontinued from the study if they  withdraw consent, if they experience an AE 
that precludes further participation, if they are non-compliant with study pr ocedures, if there is a 
protocol violation, or if treatment is discontinued due to eleva tion of SUA >6 mg/dL. The reason 
for a patient not completing the study will be co llected and recorded in  the patient’s medical 
record and on the CRF/eCRF. If a patient is disc ontinued from the study, every effort should be 
made to complete the procedures for an earl y discontinuation (see Section 3.5.4), preferably 4 
weeks after their last dose of KRYSTEXXA but sooner if necessary.  AEs that are possibly or 
probably drug-related, are of moderate or great er severity and are ongoing when a patient is 
discontinued or at the fi nal visit will be followed up to 30 days , or until the event resolves or 
stabilizes, whichever is soone r. Follow-up may entail only a phone call, or it may require 
additional examinations or laboratory evaluations , depending upon the event.  Documentation of 
the follow-up will be included in the patient’s me dical record and a summary  will be provided to 
Savient or designee for possible inclus ion in the clinical study report. 
Patients who discontinue KRYSTEXXA, for example due to an IR or an elevation of SUA >6 
mg/dL, will be asked to remain in the study in  follow-up for the remainder of their planned 
treatment duration (see Section 3.5.3).  In this case, the reason for KRYSTEXXA 
discontinuation will be collected and recorded in the patient’s medical record and on the CRF/eCRF. The medical monitor must be notifie d as soon as possible about any patient’s 
discontinuation.  
3.5.7 Gout flare Prophylaxis and Treatment 
3.5.7.1 Gout flare Prophylaxis 
All patients should receive prophyl actic treatment to reduce the ri sk of acute gout flares, unless 
medically contraindicated or not tolerated as noted in the FDA-approved KRYSTEXXA Full 
Savient Pharmaceuticals, Inc. Confidential Page 29 
Protocol M0401 FINAL  11 July 2011 KRYSTEXXA ® (pegloticase) 
 
Prescribing Information. The patient should begin a regime of colchicine  or NSAID prophylaxis 
at least 1 week before the first dose of KRYSTEXXA and it should continue for at least 
6 months after initiati on of KRYSTEXXA therapy. 
3.5.7.2 Gout flare Treatment 
An increase in gout flares is frequently obser ved upon initiation of anti- hyperuricemic therapy, 
including treatment with KRYSTEXXA. Patients are to be instructed to contact the site 
within 12 hours from the onset of symptoms. Gout flares should be confirmed through 
questioning or direct observation.  It is recommended that all pa tients who experience a gout 
flare during the study should receive an anti-inf lammatory treatment (e.g., NSAIDS, colchicine, 
corticosteroids) as clin ically deemed indicated by the treating physician.  
3.5.8 Infusion Reactions  
An IR will be defined as any AE or cluster of AE s, not attributable to another cause, that occurs 
during or within 2 hours after the infusion of KRYSTEXXA. Other cases that occur outside of 
the 2-hour window may also be categorized as an  IR as per investigator discretion. Signs and 
symptoms of the event, and treatments administ ered, must be documented in the medical record 
and in the CRF/eCRF. Examples of events not considered as possible IRs include laboratory 
abnormalities that are unlikely to have occurred  during or within 2 hours following the infusion 
(e.g., anemia, hypercholesterolemia),  gout flares, most infectious diseases, or the recurrence or 
worsening of a known chronic medical problem id entified in the pati ent’s medical history. 
3.5.8.1 Infusion Reaction Prophylaxis 
Infusion reactions are not uncommon when biolog ical agents are admini stered by i.v. infusion. 
Therefore, all patient s will receive pre-treatment prophylax is consisting of at least an 
antihistamine and corticosteroid prior to each infusion of KRYSTEXXA. In  order to standardize 
this regimen, patients will use 60 mg fexofenadine po the night before and the morning of the 
infusion and 200 mg hydrocortisone iv before the in fusion. If the investigator feels this regimen 
is not appropriate for an indivi dual patient, s/he should contact the medical monitor to discuss 
alternative therapy.  The name, dose and time of  administration of each prophylactic medication 
will be recorded in the medica l record and in the CRF/eCRF. 
3.5.8.2 Anaphylaxis 
For this study, anaphylaxis, an a llergic reaction that is  rapid in onset, can be serious, and may 
cause death, will be defined using the NIAID/F ANN diagnostic clinical cr iteria (Sampson et al, 
2006) as described in Table 1 below. This c onstellation of signs and symptoms will be 
documented in the medical record and in th e designated CRF/eCRF page. All IRs, whether 
described as anaphylaxis or not, will be adjudicated for anaphy laxis based on the criteria below 
(refer to Section 3.9).   
 
Savient Pharmaceuticals, Inc. Confidential Page 30 
Protocol M0401 FINAL  11 July 2011 KRYSTEXXA ® (pegloticase) 
 
Table 1 NIAID/FANN Clinical Criteria for Diagnosing Anaphylaxis 
Anaphylaxis is highly likely when the following criteria are fulfilled: 
Acute onset of an illness (minutes  to several hours) with involvem ent of the skin, mucosal tissue, 
or both (e.g., generalized hive s; pruritus or flushing; sw ollen lips, tongue, or uvula) 
AND  AT LEAST ONE OF THE FOLLOWING: 
a. Respiratory compromise (e.g., dyspnea, wh eeze-bronchospasm, stridor, reduced peak 
expiratory flow, hypoxemia) 
b. Reduced blood pressure (i.e., systolic blood pressure < 90 mm Hg or greater than 30% 
decrease from that person’s baseline) or a ssociated symptoms of end-organ failure (e.g., 
hypotonia [collapse], syncope, incontinence) 
NIAID/FANN: National Institute of A llergy and Infectious Disease/Food Allergy and Anaphylaxis Network 
3.5.8.3 Management of Infusion-related Adverse Events 
Refer to the Full Prescribing Information for ge neral management of in fusion-related adverse 
events.  In addition, for this st udy, if a patient experiences an IR , the following procedures will 
be undertaken: 
• an abbreviated physical examination to capture medically relevant de tails, including but 
not limited to a thorough dermatologic examin ation looking for erythema, hives or peri-
oral or lingual edema; a chest examination for breath sounds, stridor or wheezing; and a 
cardiac examination with attention to irregular heart beat. 
• vital signs (temperature, respiratory rate, he art rate, blood pressure ) will be captured at 
least every 30 minutes until the resolution or stabilization of the event. 
• a 12-lead ECG with rhythm strip will be obtai ned and analyzed for any serious IR or any 
IR with angina chest discomfort, chest tight ness, shortness of br eath, or other cardiac 
symptoms. 
• blood samples will be obtained for measurement of tryptase (as a marker for mast cell degranulation), C3, C4, and identification of an tibodies to pegloticase (IgM, IgG, IgE) or 
to PEG. 
The Investigator may administer any medically indicated pharmacologic agent intended to relieve symptoms (caution: no other drugs can  be mixed in the KRYSTEXXA infusion bag). 
Signs and symptoms of the event and drugs given fo r treatment are to be r ecorded in the medical 
record and in the CRF/eCRF. 
If in the Investigator’s opinion the patient is experiencing an anaphylacti c reaction (symptoms of 
stridor, wheezing, or cardiovascul ar instability, especially if associated with generalized 
Savient Pharmaceuticals, Inc. Confidential Page 31 
Protocol M0401 FINAL  11 July 2011 KRYSTEXXA ® (pegloticase) 
 
urticaria, pruritus, flushing, or mucosal ed ema), treatment with KRYSTEXXA should be 
permanently discontinued.  
3.6 Efficacy Assessments 
3.6.1 Serum Uric Acid Levels 
The efficacy endpoint in this study is normalizatio n of SUA to < 6 mg/dL. Serum uric acid will 
be measured using a standard clinical assay performed at local laboratories. Blood will be 
collected several days prior to each KRYSTEXXA infusion for the determination of SUA levels 
(see Section 3.5.2). 
3.6.2 Clinical Outcomes 
3.6.2.1 Number of Swollen Joints and Tender Joints 
A count of the number of swollen joints a nd tender joints will be performed at 
Baseline/Screening, at 6 months (Visit 13) and at 12 months (Vis it 26) or Early Discontinuation. 
3.6.2.2 Gout flares 
The occurrence and duration of gout flares will  be reported throughout th e study. The number of 
gout flares will be assessed by 6-week intervals for the first 3 months, and by 3-month intervals 
through the end-of-study. 
3.6.2.3 Number of Tophi 
A count of the total number of palpable subcutaneous tophi will be performed at 
Baseline/Screening, at 6 months (Visit 13) and at 12 months (Vis it 26) or Early Discontinuation. 
3.7 Safety Assessments 
3.7.1 Adverse Event Profile 
Safety assessments will be focused on a further evaluation of the AE profile of KRYSTEXXA. 
All AEs and SAEs will be monitored and recorde d. Special emphasis will be placed on capturing 
details of events that occur during the infusion or within 1 hour after the infusion of 
KRYSTEXXA in order to facilitate the characteri zation of infusion-relate d reactions, including 
anaphylaxis. As KRYSTEXXA is a biological  agent, the development of immune 
complex-related AEs will also be carefully scrutinized.  
• IRs will be defined as any AE or cluster of AEs, not attributable to another cause, that occurs during or within 2 hours after the infusion of KRYSTEXXA. Other cases that 
occur outside of the 2-hour window may also be  categorized as an IR as per investigator 
discretion. 
• Anaphylaxis will be defined using th e NIAID/FANN criteria (see Table 1). 
• Immune complex-related AEs will be defi ned as any presumptive immune complex-
related disorders that are confirmed by an a ppropriate investigation of the disease and of 
Savient Pharmaceuticals, Inc. Confidential Page 32 
Protocol M0401 FINAL  11 July 2011 KRYSTEXXA ® (pegloticase) 
 
complement markers (C3, C4 levels). Clinical  manifestations could include skin rash, 
arthralgia, arthritis, and proteinuria. 
The occurrence and duration of each confirmed gout flare will be captured as part of the safety 
assessments.  
3.7.2 Laboratory Evaluations 
Clinical laboratory tests such as hematology and blood chemistry panels are not required as part 
of this protocol. However, a blood sample will be obtained at screeni ng to evaluate G6PD 
(G6PD deficiency is an exclusion criterion). Blood will also be collected at Visit 1 to establish 
baseline values for C3, C4, and tryptase. These blood samples will be analyzed by a central 
laboratory. 
Additional blood samples for baseline antibodies to pegloticase and PEG will be drawn and 
stored frozen. These samples will be tested only for patients who subsequently have an IR, 
suspected anaphylaxis, or suspected immune comp lex disease, to be compared with samples 
obtained at the time of the AE. These antibody an alyses will be performed by the designated 
bioanalytical laboratory. 
3.7.3 Vital Signs 
Vital signs will consist of pulse rate, sitting blood pressure and body temperature (taken either 
orally or aurally).  
3.7.4 Physical Examination 
Physical examinations will be performed by body system at the Screening and Visit 27 or Early 
Discontinuation Visit. Breast, genitourinary and rectal examinations may be excluded at the 
discretion of the Investigator. 
Significant findings prior to the administrati on of KRYSTEXXA must be recorded in the 
patient’s medical record and included on th e Medical History CRF/eCRF page. Significant 
findings that occur after administration of KRYSTEXXA which meet the definition of an AE 
must be recorded in the medical record  and on the Adverse Events CRF/eCRF page. 
3.7.5 Antibody Formation 
For patients experiencing an IR, suspected anap hylaxis, or suspected i mmune complex disease, 
both baseline samples and samples obtained at the time of the AE will be assessed by a designated bioanalytical laboratory for the presence of antibodies. Validated 
enzyme-linked 
immunosorbant assays  (ELISAs) will be performed by the de signated bioanalytical laboratory to 
detect antibodies directed against pegloticase (IgG, IgM and IgE) and against the PEG portion of 
pegloticase (pan-anti-PEG). 
Savient Pharmaceuticals, Inc. Confidential Page 33 
Protocol M0401 FINAL  11 July 2011 KRYSTEXXA ® (pegloticase) 
 
3.8 Adverse Events 
3.8.1 Adverse Event Definitions 
3.8.1.1 Adverse Event 
An AE is any untoward event whether or not considered related to the use of KRYSTEXXA. 
Any worsening (i.e. any clinically  significant adverse change in frequency or intensity) of a 
preexisting condition which is temporally asso ciated with the use of KRYSTEXXA is also 
considered an AE. Abnormal laboratory values or test results constitute AEs only if they induce 
clinical signs or symptoms or require therapy, and are recorded on the Adverse Events 
CRF/eCRF under the signs, symptoms or diagnosis associated with them. 
Baseline conditions should not be considered ad verse experiences; however, worsening of a pre-
existing condition may be considered an AE. Changes resulting from  normal growth and 
development which do not vary significantly in fre quency or severity from expected levels are 
not to be considered adverse experiences. An ex ample of this may include, but is not limited to, 
menopause. 
The sponsor will report all AEs according to appr opriate health authority (e.g., FDA) guidelines 
and regulations. 
3.8.1.2 Serious Adverse Event 
An SAE is any AE occurring that results in any of the following outcomes:  
• Death  
• Is life-threatening (places the patient, in the vi ew of the Investigator, at immediate risk of 
death from the event as it occurred) 
• Inpatient hospitalization or prolongation of existing hospita lization (hospitalization is 
defined as an inpatient admission, regardless of  length of stay, even if hospitalized as a 
precautionary measure for continued observation) 
• A permanent, persistent or si gnificant disability (substantial disruption of the ability to 
conduct normal life functions) 
• A congenital anomaly/birth defect 
• Is the result of an overdose  
• A medically significant event th at may jeopardize the patient and may require medical or 
surgical intervention to prevent one of the outcomes listed in this definition 
Events NOT considered to be SAEs are:  
• Hospitalization for treatment, which was el ective or pre-planne d, for a pre-existing 
condition that did not worsen 
• Treatment on an emergency, outpatient basis for an event NOT fulfilling any of the 
definitions of serious given above and NOT resulting in hospital admission 
Savient Pharmaceuticals, Inc. Confidential Page 34 
Protocol M0401 FINAL  11 July 2011 KRYSTEXXA ® (pegloticase) 
 
• An AE that, had it occurred in a more  severe form, might have caused death 
3.8.1.3 Adverse Event Classifications 
Safety assessments in this study include an ev aluation of the frequency and severity of IRs, 
anaphylaxis, and immune complex-related events. For the purposes of this study, these events 
shall be defined as follows: 
• IRs will be defined as any AE or cluster of AEs, not attributable to another cause, that 
occurs during or within 2 hours after the infusion of KRYSTEXXA. Other cases that 
occur outside of the 2-hour window may also be  categorized as an IR as per investigator 
discretion. 
• Anaphylaxis will be defined using the NIAI D/FANN criteria: acute onset of an illness 
(minutes to several hours) with involvement of the skin, mucosal tissue, or both 
(e.g., generalized hives; prur itus or flushing; swollen lips, tongue, or uvula) AND  AT 
LEAST ONE OF THE FOLLOWING: 
a. Respiratory compromise (e.g., dyspnea, wheeze-bronchospasm, stridor, reduced peak expiratory flow, hypoxemia 
b. Reduced blood pressure (i.e., systolic bl ood pressure < 90 mm Hg or greater than 
30% decrease from that person’s baseline) or associated symptoms of end-organ 
failure (e.g., hypotonia [collapse], syncope, incontinence) 
• Immune complex-related disorders are caused by the deposition of immune complexes in 
small blood vessels in the body. Th is can result in the onset of  diverse disorders such as 
glomerulonephritis, skin vascul itis, or arthritis. For the purpose of this study, any 
presumptive diagnosis of any of these conditi ons will call for a clinic al investigation of 
the disease and of complement markers (C3, C4). If both the clinical and laboratory 
investigations are confirmatory, the disorder will be classified as an immune complex-related AE. 
3.8.2 Adverse Event Evaluation Criteria 
3.8.2.1 Relationship 
The determination of the likelihood that KRYSTEXXA caused an AE will be provided by the Investigator. The Investigator’s  signature and date on the so urce document and CRF/eCRF that 
supports the causality noted on the AE form ensures that a medically qualified assessment of causality has been done. The assessment of re lationship will be reported by the Investigator 
according to his/her best clinical judgment. The following scale of criteria may be used as a 
guidance (not all criteria must be present in order to be indicative of a drug relationship). 
Probably related to the drug: 
• There is evidence of exposure to the drug 
• The temporal sequence of the AE onset relative to administration of the drug is reasonable 
Savient Pharmaceuticals, Inc. Confidential Page 35 
Protocol M0401 FINAL  11 July 2011 KRYSTEXXA ® (pegloticase) 
 
• The AE is more likely explained by the drug than by another cause 
Possibly related to the drug: 
• There is evidence of exposure to the drug 
• The temporal sequence of the AE onset relative to administration of the drug is reasonable 
• The AE could have been due to another equally likely cause 
Unlikely related to the drug: 
• There is evidence of exposure to the drug 
• There is another more likely cause of the AE 
• There is no temporal relationship to the drug 
3.8.3 Adverse Event Reporting 
Information about all AEs, discovered by Investig ator or detected through physical examination, 
laboratory test or other means, will be collected and recorded on the Adverse Event CRF/eCRF 
and followed as appropriate.  
As far as possible, each AE will also be described by: 
• its duration (start and end dates) 
• its relationship to KRYSTEXXA (unlikely, possibly, or probably) 
• the action(s) taken and, as relevant, the outcome 
ANY SERIOUS ADVERSE EVENT OR DEATH DU E TO ANY CAUSE THAT OCCURS IN 
ANY PATIENT IN THIS STUDY, WHETHER OR NOT RELATED TO KRYSTEXXA, 
MUST BE REPORTED WITHIN 24 HOURS TO  ONE OF THE INDIVIDUAL(S) LISTED ON 
THE CONTACT INFORMATION PAGE. ALL PATIENTS WITH SERIOUS ADVERSE EXPERIENCES MUST BE FOLL OWED UP FOR OUTCOME. 
3.9 Adjudication Committees 
Two clinical adjudication committees will be estab lished for this study to adjudicate the adverse 
events reported for events of special interest.  The first of these will be a committee comprised of physicians with experience in immunology and allergic reactions. This immunologic 
adjudication committee will be charged with adjudicating all IRs and cases reported as anaphylaxis to determine if they meet the NIAID/FANN clin ical criteria for diagnosing 
anaphylaxis (see Table 1), based on the described signs and sympto ms. Any AEs that have been 
described as immune-complex related disease wi ll also be evaluated by this expert group, to 
assess whether the diagnosis has been confirmed by appropriate clinical a nd laboratory criteria.  
In addition, a cardiovascular event adjudication committee, comprised of physicians experienced 
in this area, will review each potential cardiovascular (CV) adverse event to determine whether or not it meets the diagnosis of a CV  event based on established criteria.  
Savient Pharmaceuticals, Inc. Confidential Page 36 
Protocol M0401 FINAL  11 July 2011 KRYSTEXXA ® (pegloticase) 
 
3.10 Steering Committee 
A protocol Steering Committee will be appointed to  periodically review safety reports from the 
study, as well as the reports from the two inde pendent clinical adjudication committees.  The 
Steering Committee will evaluate these reports an d provide assessments to the Savient Senior 
Management, including the Savient Chief Medical Officer. 
4 PROTOCOL AMENDMENTS, OT HER CHANGES IN STUDY 
CONDUCT 
4.1 Protocol Amendments 
Any changes to the protocol will be made in th e form of an amendment. Unless the changes are 
designed to eliminate an apparent immediate h azard to patients, both Savient and the governing 
IRB must grant approval of the amendment be fore any changes may be implemented in study 
conduct.  
4.2 Other Changes in Study Conduct 
Changes in study conduct are not permitted. Any unforeseen changes in study conduct will be 
recorded in the clinical study report. 
5 DATA MANAGEMENT 
5.1 Data Collection 
Investigators or their designees will enter study data in the CRFs /eCRFs and ensure the data is 
accurate and complete and that all entries are ve rifiable with source documents. Study monitors 
will review data in the CRFs/eCRFs for complete ness and accuracy, and instruct site personnel 
to make any required corrections or additions in a manner compliant  with Good Clinical Practice 
(GCP) guidelines. 
5.2 Database Management and Quality Control 
Information entered into the database is subjec ted to systematic logic and consistency checking 
routines. Obvious errors will be  corrected by the appropriate data management personnel in 
accordance with the data handling and entry guid elines for the study. Findings from the process 
are reviewed by qualified Data Management or C linical personnel, after which query forms are 
returned to the investigational site for resoluti on of key variables. Each site is expected to 
respond promptly to data queries. All queries related to AEs must be signed by an investigator. 
Periodic quality control edit checks of key safety and efficacy data in the database will be made 
throughout the duration of the study. 
Concomitant medications entered into the database will be coded using the World Health 
Organization Drug Dictionary whic h classifies according to ther apeutic/pharmacological class. 
Coexistent diseases and AEs will be coded using the Medical Dictionary for Regulatory 
Activities (MedDRA).  
Savient Pharmaceuticals, Inc. Confidential Page 37 
Protocol M0401 FINAL  11 July 2011 KRYSTEXXA ® (pegloticase) 
 
When the database has been declared to be comp lete and accurate, the database will be locked. 
Any changes to the database afte r that time can only be made by joint written agreement between 
the Savient Clinical, Statistical and Data Management Directors. 
6 STATISTICAL METHODS 
6.1 Statistical Methods 
The statistical analysis will be coordinated by the responsible biostatistician. The Statistical 
Analysis Plan (SAP) will provide additional deta ils on the planned statistical analysis. The SAP 
will be finalized before the database is locked. Any deviations from the SAP will be described in 
the clinical study report. 
Descriptive statistics (number of  patients, mean, standard deviat ion [SD], minimum, median, and 
maximum) will be used to summarize continuous va riables. Descriptive statistics for categorical 
variables will consist of frequency and percentage. 
6.1.1 Population 
The analyses will be performed on the Intent -to-Treat (ITT) populati on. The ITT population will 
be comprised of all enrolled patients who received at least 1 dose of KRYSTEXXA and have 
some follow-up data. 
6.1.2 Background and Demographic Characteristics 
Demographics and other baseline characteristi cs will be summarized for the ITT population 
using standard descriptive statis tics (number of patients, mean a nd standard deviation, minimum, 
median, and maximum), which will be reported a nd updated for all baseline variables at each 
data review. All categorical/qua litative data will be presente d using absolute and relative 
frequency counts and percentages. The total number of subjects in the treatment group 
overall (N) will be used as the denominator for percentage calculations, unless stated otherwise 
in the SAP. The prediction and profile of the patient’s accrual will be made at each review. 
6.1.3 Study Medication 
Summary statistics for the total exposure to  KRYSTEXXA during the treatment period (number 
of KRYSTEXXA infusions ) will be tabulated. 
6.1.4 Concomitant Therapy 
Concomitant medications will be summarized by th erapeutic/pharmacological class. In addition, 
they will be listed by treatment group, name of drug, dates administ ered and indication. 
6.1.5 Efficacy Evaluation 
One efficacy endpoint in this study is normalizati on of SUA to < 6 mg/dL. Descriptive statistics 
will be employed to summarize the proportion of responders, where a responder is defined as a 
patient whose SUA values were < 6 mg/dL at their final 2 consecutive  study visits. Summary 
statistics will be provided for the number of swo llen joints and tender joints at baseline, 6 months 
Savient Pharmaceuticals, Inc. Confidential Page 38 
Protocol M0401 FINAL  11 July 2011 KRYSTEXXA ® (pegloticase) 
 
(Visit 13) and 12 months (Visit 26) or Early Discontinuation;  for changes in numbers of gout 
flares based on patient reported hi story at 6-week intervals for Months 1-3 and 3-month intervals 
thereafter; and for elimination of tophi, i.e., the number of patients with a reported tophus 
resolution at 6 months (Visit 13) and 12 months (Visit 26 ) or Early Discontinuation.  
It is anticipated that there may be a considerab le number of study patient s who will drop out of 
the study. The sponsor will make every effort to identify the reason(s) for dropout before 
reaching the primary safety endpoint. For the analysis of each efficacy endpoint, various sensitivity analyses will be performed under different assumptions of potentially informative dropouts. For example, in the responder analysis, one analysis will be based on the ITT population with various imputation methods for missi ng values at the end. Analyses will also be 
performed assuming all “informative” dropouts are non-responders. For continuous efficacy variables, sensitivity analyses will be performed using standard mixed-effect model repeated measure (MMRM) methods. All the analyses will be summarized using 95% confidence interval estimates. The resulting summarized statistics fo r efficacy will be compared to those reported 
from the pre-approval Phase 3 studies. 
6.1.6 Safety Evaluation 
Adverse events will be summarized by presenti ng the proportion of patients having any AE, 
overall and by body system, and by event as defi ned by the MedDRA preferred term. Separate 
summary tables will be provided for IRs, anaphylaxis AEs, and immune complex-related AEs.  
For each type of the primary safety endpoints, one event, at most, will be counted per patient. 
The 95% (exact) confidence interval estimates for each type of safety endpoint will be reported 
for the rate of incidence at th e final analysis. The following hypothe sis will be specifically tested: 
the rate of IRs seen in the Phase 3 studies will be reduced in this study by monitoring SUA prior 
to infusions and discontinuing therapy if levels increase to above 6 mg/d L, particularly when 
2 consecutive levels above 6 mg/dL are observed. With at least 500 patients enrolled with 1 year 
follow-up, the power of detecting a 26% IR rate (the observed value from the pre-approval Phase 
3 studies) against 13% is at least 90%. The rate of IRs reported during th e study will be reported 
and compared descriptively to the rates obser ved in the pre-approval Phase 3 studies.  
Descriptive statistics for laboratory values, v ital signs, and their changes from baseline will be 
provided. Safety data will be listed as appropriate. Further details will be specified in the SAP. 
6.1.7 Interim Analysis 
There is no planned interim analysis. Howeve r, the number of enrolled patients will be 
reassessed approximately 2 years after the first patie nt is enrolled. This data will be utilized to 
make a prediction concerning the future enrollment profile. The enrollment goal may be adjusted depending on the drop-out rate such that appr oximately 500 patients will complete the 1 year 
treatment period. 
Savient Pharmaceuticals, Inc. Confidential Page 39 
Protocol M0401 FINAL  11 July 2011 KRYSTEXXA ® (pegloticase) 
 
6.1.8 Reports to the Adjudication Committees 
Periodically, reports of signs and symptoms associ ated with infusion reac tions, cases reported as 
anaphylaxis, and events described as immune-com plex related, will be provided to the clinical 
immunologic adjudication committee for their review. 
Similarly, the cardiovascular adjudication committee will be provided with lis tings for all serious 
adverse events and non-serious adverse events with preferred term s that are potentially 
cardiovascular in nature. 
6.2 Sample Size 
Approximately 1500 patients will be enrolled in order to observe treatment of up to 500 patients 
for one year. This target sample size is based on clinical judgment and is  thought to be adequate 
to allow for a robust assessment of key safety and efficacy features. No formal statistical sample 
size calculation has been performed. 
7 PROCEDURES AND INSTRUCTIONS 
7.1 Packaging, Labeling, Storage, and Return of Clinical Supplies 
KRYSTEXXA ® (pegloticase), the reference therapy in  this post-market observational study, is 
commercially available. Please refer to th e FDA-approved KRYSTEXXA Full Prescribing 
Information for specifics regarding handling a nd storage. Used or unused material may be 
destroyed at the healthcare faci lity according to standard institu tional procedures. No material 
should be returned to Savient. 7.2 Drug Administration 
7.2.1 Dose Preparation 
Visually inspect KRYSTEXXA fo r particulate matter and discol oration before administration, 
whenever solution and container pe rmit. Do not use vials if either  is present. Use appropriate 
aseptic technique. Withdraw 1 mL  of KRYSTEXXA from the vial into a sterile syringe. Discard 
any unused portion of product remaining in the vial. Inject into a single 250 mL bag of 0.45% or 
0.9% Sodium Chloride Injection, USP for i.v. infusion. Do not mix or dilute with other drugs. Invert the infusion bag containi ng the dilute KRYSTEXXA solution a number of times to ensure 
thorough mixing. Do not shake. 
KRYSTEXXA diluted in infusion bags  is stable for 4 hours at 2 °C to 8°C (36°F to 46°F) and at 
room temperature (20°C to 25°C, 68°F to 77 °F). However, it is recommended that the diluted 
solution be stored under refriger ation, not frozen, protected fro m light, and used within 4 hours 
of dilution. Before administration, allow the diluted solution of KRYSTEXXA to reach room 
temperature. KRYSTEXXA in a vial  or in an i.v. infusion fluid should never be subjected to 
artificial heating. 
Savient Pharmaceuticals, Inc. Confidential Page 40 
Protocol M0401 FINAL  11 July 2011 KRYSTEXXA ® (pegloticase) 
 
7.2.2 Dose Administration 
Do not administer as an intravenous push or bolus. 
Monitoring Therapy: The risk of anaphylaxis and IRs is higher in patients who have lost 
therapeutic response. Serum uric acid (SUA) levels will be monitored prior to infusion and 
therapy will be discontin ued if levels increase above 6 mg /dL on two consecutive measurements.  
If the SUA is noted to be above 6 mg/dl the s ponsor suggests that a repeat SUA should be drawn 
when the result is noted to confirm, and if the 2 consecutive levels are noted to be above 6 mg/dL 
then it is advised to discontinue therapy.  
The KRYSTEXXA admixture should only be administered by i.v. infusion over no less than 
120 minutes via gravity feed, sy ringe-type pump, or infusion pump. Patients should receive pre-
infusion medications (antihistamines and corticoste roids) to minimize the ri sk of anaphylaxis and 
IRs. Administer KRYSTEXXA in a healthcare setti ng and by healthcare providers prepared to 
manage anaphylaxis and IRs, and observe patie nts for an appropriate period of time after 
administration.  
Refer to the KRYSTEXXA Full Prescribing Informa tion for management of an IR . Since IRs 
can occur after completion of the infusion, obser vation of patients for approximately an hour 
post-infusion is recommended. 
Savient Pharmaceuticals, Inc. Confidential Page 41 
Protocol M0401 FINAL  11 July 2011 KRYSTEXXA ® (pegloticase) 
 
 
8 REFERENCE LIST 
1. Arellano F and Sacristan JA: Allopurinol hypersensitivity syndrome: a review. Ann 
Pharmacother  1993; 27:337-43.  
2. Becker MA and Jolly M: Clinical gout and the pathogenesis of hyperuricemia. In: Arthritis 
and Allied Conditions, 15th ed  Philadelphia: Lippincott, Williams, and Wilkins 2005: 
p 2303-40.  
3. Chen SM: Serum Sickness. Updated 28 April 2010. WebMD; 
http://emedicine.medscape. com/article/756444-overview  Accessed on 4 Nov 2010. 
4. Dalbeth N and Haskard DO: Mechanisms of inflammation in gout. Rheumatology 2005; 
44:1090-6. Epub 2005 Jun 14.  
5. Hande KR, Noone RM, and Stone WJ: Severe allopurinol toxici ty. Description and 
guidelines for prevention in patients with renal insufficiency. Am J Med  1984; 76:47-56.  
6. Kanellis J, Kang D-H, Feig D, and Johnson RJ: Asymptomatic hyperuricemia. In: Crystal-
Induced Arthropathies (Wortmann RL, et al), New York : Taylor and Francis 2006: p 81-97.  
7. Sampson HA, Munoz-Furlong A, Campbell RL, Adkinson NF, Jr., Bock SA, Branum A, 
et al: Second symposium on the definition a nd management of anaphylaxis: summary report-
-Second National Institute of Allergy and Inf ectious Disease/Food Allergy and Anaphylaxis 
Network symposium. J Allergy Clin Immunol  2006;117(2):391-7.  
8. Singer JZ and Wallace SL: The allopurinol hypersensitivity syndrome. Unnecessary 
morbidity and mortality. Arthritis Rheum  1986; 29:82-7.  
9. Stamp L, Gow P, Sharples K, and Raill B: The optimal use of allopurinol: an audit of 
allopurinol use in South Auckland. Aust NJ J Med  2000; 30:567-72.  
10. Wu X, Muzny DM, Lee CC, and Caskey CT: Two independent mutational events in the loss of urate oxidase during hominoid evolution. J Mol Evol  1992; 34:78-84.
 
Savient Pharmaceuticals, Inc. Confidential Page 42 
Protocol M0401 FINAL  11 July 2011 KRYSTEXXA ® (pegloticase) 
 
Appendices 
 
Appendix Number  Appendix Title 
1 Administrative Procedures 
2 Ethics and Good Clinical Practice 
3 Schedule of Procedures and Evaluations 
 
Savient Pharmaceuticals, Inc. Confidential Page 43 
Protocol M0401 FINAL  11 July 2011 KRYSTEXXA ® (pegloticase) 
 
Appendix 1: Administrative Procedures 
1. Changes to the Protocol 
Any change or addition to this protocol requir es a written protocol amendment that must be 
approved by Savient before implementation. Ame ndments significantly affecting the safety of 
patients, the scope of the investigation or the scientific quality of the study, require additional 
approval by the IRB of all centers. A copy of the written approval of the IRB must be given to 
the study monitor.  
Amendments affecting only administrative aspect s of the study do not require formal protocol 
amendments or IRB approval, but the IRB of each center must be kept informed of such 
administrative changes.  
2. Monitoring Procedures 
Investigational sites will be monitored on a regular basis according to vendor monitoring 
standard operating procedures (SOPs) and st udy specific monitoring guidelines to assure 
satisfactory data recording, adherence to the pr otocol and GCP. The frequency of monitoring 
may vary depending on enrollment rate and the quan tity of data collection, but must occur at 
least yearly. The Investigator and staff are expected  to assist with the st udy monitor’s review of 
all relevant study documentation, including source documents for each study patient. It is essential that the Investigator  and study coordinator set aside a sufficient amount of time for 
these visits to permit an adequate review of the study’s progress and of completed CRFs/eCRFs. 
The Investigator must give the m onitor access to relevant hospital or  clinical records, to confirm 
their consistency with the CRF/eCRF entries. No information in these reco rds about the identity 
of the patients will l eave the study center.  
3. Data Collection 
CRFs/eCRFs for the study will be provided. The I nvestigator or designee must complete the 
CRFs/eCRFs and transmit the data as instructed at st udy initiation and must store a copy of the 
CRF/eCRF with other study documen ts, e.g. the protocol, the inve stigators’ brochure and any 
protocol amendments, in a secure place. All entries to the CRFs/eCRFs must be made as 
described in the CRF/eCRF Comp letion Instructions or as in structed at study initiation. 
Data on patients collected on CRF/eCRFs during the study will be documented in an anonymous 
fashion and the patient will only be identified by  the patient number, and by his/her initials if 
also required. If, as an excepti on, it is necessary for safety or regulatory reasons to identify the 
patient, Savient (and its representa tives) and the Investigator ar e bound to keep this information 
confidential. 
Discrepancies or questions concerning the data will be sent to the Investigator by means of a 
systematic query resolution process. The discre pancy reports (“queries”)  should be resolved by 
Savient Pharmaceuticals, Inc. Confidential Page 44 
Protocol M0401 FINAL  11 July 2011 KRYSTEXXA ® (pegloticase) 
 
the investigator or study staff, signed and dated, and returned as instructed at study initiation. A 
copy of the discrepancy report must  be retained in the patient bi nder as a record of changes or 
acknowledgment of the receip t of queries on the data.  
The Investigator must maintain source documents  for each patient in the study, consisting of all 
demographic and medical information, including la boratory data, etc, and keep the original  
signed and dated IC form. All information on CRF s/eCRFs must be traceable to these source 
documents kept in the patient's file. Data obtained without a separate written or electronic source 
document will be defined before study start and will be recorded directly on the CRFs/eCRFs, 
which will be documented as being the source data.  
4. Document Retention 
Essential documents, as listed below, must be re tained by the Investigator for as long as needed 
to comply with national and international regulati ons (generally 2 years af ter the last marketing 
approval). Savient will notify the Investigator(s)/in stitution(s) when the study-related records are 
no longer required. If the Investigator relocates, retires, or for any reason can not keep the study records, the records may be transferred to an a cceptable designee. Savient must be notified in 
writing of the name, address, and telephone number of the person designated  to retain the study 
records. The Investigator agrees to adhere to the document retention procedures by signing the 
protocol.  
Essential documents include: 
• IRB approvals for the study protocol and all amendments 
• All source documents incl uding laboratory records 
• CRF/eCRF copies 
• Data change forms or data queries 
• Patients' original signed, dated IC form s (with study number and title of study) 
• Monitoring logs and appointment schedules 
• Food and Drug Administration (F DA) form 1572 (as required) 
• Investigator(s) curriculum v itae, medical license informa tion, and financial disclosure 
documentation 
• All sponsor/investigator corres pondence, including telephone logs 
• Any other pertinent study document  
5. Disclosure and Confidentiality 
By signing the protocol, the Inves tigator agrees to keep all in formation provided by Savient (or 
representatives) in strict confidence and to requ est similar confidentiality from his/her staff and 
the IRB. Study documents provide d by Savient or representatives (e.g., protocols, investigators' 
Savient Pharmaceuticals, Inc. Confidential Page 45 
Protocol M0401 FINAL  11 July 2011 KRYSTEXXA ® (pegloticase) 
 
brochures, CRFs and other material) will be stored appropriately to ensure their confidentiality. 
The information provided by Savient or representa tives to the Investigator  may not be disclosed 
to others without direct written  authorization from Savient. Data generated by this study will be 
considered confidential by the Investigator except to the extent that it is included in a publication 
as provided in Appendix 1 Secti on 6. Publication of results. 
Individual patient data obtained during this study  are confidential and will not be disclosed to 
third parties with th e following exceptions: 
• When data are needed by the patient’s pe rsonal physician or other medical personnel 
responsible for the patient’s welfare. Prior written consen t from the patient or legal 
guardian must first be obtained. 
• For data inspection and verification by Savient or designees (e.g., sponsor’s 
representatives), IRB or regulat ory agency representatives. 
Individual patient identity  cannot be divulged in any communication or publication. 
6. Publication of Results 
Any formal presentation or publication of data from this study will be considered as a joint 
publication by the Investigator(s) and appropria te Savient personnel. Authorship will be 
determined by mutual agreement. For multicente r studies, it is mandatory that the first 
publication is based on data from a ll centers that has been analyzed as stipulated in the protocol. 
Investigators participating in multicenter studies ag ree not to present data gathered from 1 center 
or a small group of centers before the full public ation, unless formally agreed to by all other 
Investigators and Savient. 
Savient must receive copies of any intended co mmunication in advance of  publication (at least 
15 working days for an abstract or oral pr esentation and 45 working days for a journal 
submission). Savient will review the communications for accur acy (thus avoiding potential 
discrepancies with submissions to health authorities), verify that confidential information is not 
being inadvertently divulged and provide any rele vant supplemental information. In accordance 
with uniform criteria for manuscripts, Savient w ill impose no impediment, direct or indirect, on 
publication of the study’s full results, including data  perceived to be detrimental to the product. 
7. Discontinuation of Study 
Savient reserves the right to di scontinue any study under the conditi ons specified in the clinical 
study agreement. In the event that Savient prem aturely terminates a particular study site for 
cause, Savient will promptly notify that site’s IRB. 
8. Changes in Study Personnel 
If there is a change of any personnel listed on the FDA form 1572, a new form reflecting the change must be completed and forwarded to the designated vendor including, when applicable, 
Savient Pharmaceuticals, Inc. Confidential Page 46 
Protocol M0401 FINAL  11 July 2011 KRYSTEXXA ® (pegloticase) 
 
any new staff member’s signed curriculum vitae, medical license (as appropriate), and signed 
financial disclosure statement. 
Appendix 2: Ethics and Good Clinical Practice 
This study must be carried out in compliance wi th the protocol and in accordance with the 
standard operating procedures of the sponso r’s representative fo r study conduct (contract 
research organization [CRO]). These requirements ar e designed to ensure adherence to GCP, as 
described in:  
• International Conference on Harmonization (ICH)  Harmonized Tripartite Guidelines for 
Good Clinical Practice 1996. 
• Directive 91/507/EEC, The Rules Governing Medicinal Products in the European 
Community. 
• US 21 Code of Federal Regulations dealing wi th clinical studies (i ncluding parts 50 and 
56 concerning informed consent and IRB regulations). 
• Declaration of Helsinki (most current version), concerning medical research in humans  
The investigator agrees, when signi ng the protocol, to adhere to the instructions and procedures 
described in it and thereby to adhere to the principles of GCP that it conforms to.  
1. Institutional Review Board/ Independent Ethics Committee 
Before implementing this study and initiating any protocol-related activities, the protocol, the 
proposed IC form and other information provided to patients must be reviewed by a properly 
constituted IRB. A copy of the si gned and dated statement that th e protocol and IC have been 
approved by the IRB must be sent to the CRO before study initiation. The Investigator must 
maintain the original approval letter that contains the study number , protocol title, and 
identification of all documents approved. The Department of Health and Human Services 
(DHHS) assurance number or statement of compliance with relevant Federal Regulations 21 
CFR §56, or the name and occupation of the chairm an and the members of the IRB must also be 
supplied to the CRO. If the Investigator or any me mber of the study staff is also a member of the 
IRB, he or she must provide a written statemen t that he/she absented from voting on this study. 
Any amendments to the protocol, other than admi nistrative ones, must also be approved by the 
IRB.  
The Investigator must submit annua l status reports to the IRB a nd provide a copy to the CRO. As 
soon as possible after completion or termination of  the study a final report must be submitted to 
the IRB and the CRO. The Investigator must main tain an accurate and complete record of all 
submissions made to the IRB including a list of all reports and documents submitted. The IRB will comply with all federal, state, and local laws. The Investigator will obtain from the 
IRB and submit to the CRO a signed statement indicating that it complies with GCP. The 
sponsor (Savient) and the sponsor’s representa tive (CRO) will promptly be advised of any 
Savient Pharmaceuticals, Inc. Confidential Page 47 
Protocol M0401 FINAL  11 July 2011 KRYSTEXXA ® (pegloticase) 
 
regulatory inspection relating to th is study of either the instituti on or the IRB. The Investigator 
will promptly provide a copy of any inspection report. 
2. Informed Consent 
The Investigator must explain to each patient or  patient’s legally authorized representative the 
nature of the study, its purpose, the procedures involved, the expected  duration, the potential 
risks and benefits involved and any discomfort it may entail. Each patient or patient’s legally 
authorized representative must be informed that participation in the study is voluntary and that 
he/she may withdraw from the study at any time and that withdrawal of consent will not affect 
his/her subsequent medical treatment or relationship with th e treating physician. 
This informed consent should be given by m eans of a standard statement, written in 
non-technical language. The patient  should read and consider the statement before signing and 
dating it, and should be given a copy of the signed document. No patient can enter the study 
before informed consent has been obtained. 
The study-specific IC form must be submitted by the Investigator with the protocol for IRB 
approval. The CRO will supply a proposed IC form, which complies with regulatory 
requirements and is considered appropriate for the study. Any ch anges to the proposed consent 
form suggested by the Investigator must be agreed to by the CRO and Savient, and a copy of the 
approved version must be provided to  the monitor after IRB approval. 
3. Compliance with Law, Audit, and Debarment 
By signing this protocol, the Investigator agrees  to conduct the study in an efficient and diligent 
manner and in conformance with this protocol , with generally accepted standards of GCP and 
with all applicable federal, state, and local la ws, rules and regulations relating to the conduct of 
the clinical study. 
The Investigator also agrees to allow monitoring, audits, IRB review and regulatory agency 
inspection of study-related documents and proce dures and provide for direct access to all 
study-related source data and documents. The Investigator agrees not to seek reimbursement from patients, their insurance providers, or 
from government programs for procedures includ ed as part of the study reimbursed to the 
Investigator by Savient.  The Investigator shall prepar e and maintain complete and accurate study documentation in 
compliance with GCP standards and applicable federal, state, and local laws, rules and 
regulations. For each patien t participating in the study, the Inves tigator shall provide all data and 
submit any other reports to the CRO as required by this protocol or by any other agreement with 
Savient.  Study documentation will be promptly and fully disclosed to the CRO and Savient by the 
Investigator upon request and also shall be made available at the Investigat or’s site upon request 
for inspection, copying, review and audit at reasonab le times by representatives of Savient or any 
Savient Pharmaceuticals, Inc. Confidential Page 48 
Protocol M0401 FINAL  11 July 2011 KRYSTEXXA ® (pegloticase) 
 
regulatory agencies. The Investigat or agrees to promptly take any reasonable steps that are 
requested by Savient as a result of an audit to correct deficiencies in the study documentation and 
CRF/eCRFs. 
Persons debarred from conducting or working on clinical studies by a ny court or regulatory 
agency will NOT be allowed to conduct or wo rk on Savient studies. The Investigator will 
immediately disclose in writing to Savient if any person who is involved in conducting the study 
is debarred, or if any proceeding for debarment is  pending or, to the best of the Investigator’s 
knowledge, threatened. 
4. Compliance with Financial Disclosure Requirements 
By signing this protocol, the Inve stigator agrees to provide to Savient or their representatives 
accurate financial information to allow submission of complete and accu rate certification and 
disclosure statements as requi red by US FDA regulations (21 CF R Part 54). This requirement 
also extends to subinvestigators. 
Savient Pharmaceuticals, Inc. Confidential Page 49 
Protocol M0401 FINAL  11 July 2011 KRYSTEXXA ® (pegloticase) 
 
Appendix 3.  Visit Schedules and Assessments 
 
1.    Schedule of Procedures and Evaluations  
Study Period Pre-
treatment Treatment Period Follow-
up 
Visit Screening / 
Enrollment 1 
Baseline2-12 13 14-25 26 27 
Week Up to 2 weeks 
prior to 
treatment 1 3-23 25 27-49 51 63 
Procedures        
Informed consent, Medical 
History, Height and Weight X       
Physical examination, vital signs X      X 
Gout history and symptom 
severity X       
Blood sample for G6PD X       
Review concomitant  medications X X X X X X X 
Initiate gout flare prophylaxis X       
Acute gout flare assessment  X X X X X X 
Swollen/tender joint count X   X  X  
Tophus assessment X   X  X  
Blood samples to monitor SUA 
after infusions X X X X X X  
Blood samples for tryptase, antibody and C3 and C4 testing  X     X1 
Premedicate, obtain vital signs  X X X X X  
Administer KRYSTEXXA after pre-medicating, monitor infusions  X X X X X  
Assess for adverse events  X X X X X X 
 
Note: C3 = complement component 3; C4 = complement component 4; G6PD = glucose-6-phosphate 
dehydrogenase; SUA = serum uric acid 
X1 Antibody samples only 
 
Savient Pharmaceuticals, Inc. Confidential Page 50 
Protocol M0401 FINAL  11 July 2011 KRYSTEXXA ® (pegloticase) 
 
2.    Schedule of Procedures and Evalua tions for Patients in Follow-up after Early 
KRYSTEXXA Discontinuation 
 
Study Period Post-Treatment Period 
Visit 4-wks post 
infusion# 3 months 
post-tx# 6 months 
post-tx* 9 months 
post-tx* 12 months 
post-tx* 
Week      
Procedures      
Physical examination X     
Review concomitant  medications X X X X X 
Adverse event assessment X X X X X 
Swollen/tender joint count X     
Vital signs X     
Tophus assessment X     
Blood samples for SUA X     
Blood samples for antibodies X X X X X 
# All patients continuing in follow-up after early KRYSTEXXA discontinuation will have these 
visits. 
* Patients in post-treatment follow-up after early  discontinuation of KRYSTEXXA will be followed 
only for the planned 1-year duration of their participation. Therefore, depending on when treatment was discontinued for an individual patient, these visits may not be applicable. 
Savient Pharmaceuticals, Inc. Confidential Page 51 
Protocol M0401 FINAL  11 July 2011 KRYSTEXXA ® (pegloticase) 
 
3.    Serum Sample Collections  for Specified Adverse Events 
 
Adverse Event Collect serum sample for assessment of: 
Infusion-related AE Anti-pegloticase, anti-PEG , anti-pegloticase IgE, tryptase, C3, C4 
Potential immune-
complex AE Anti-pegloticase, anti-PEG, anti-pegloticase IgE, C3, C4 
 